ProCE Banner Activity

Key Decision Points in Neoadjuvant and Adjuvant Treatment Selection for Early-Stage HER2-Negative Breast Cancer

PDF

Download this summary resource for a quick guide to treatment algorithms and considerations for perioperative management of early-stage HER2-negative breast cancer.

Released: August 28, 2023

Share

Faculty

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, Bydonis, Carrick Therapeutics, BioNTech, Daiichi Sankyo, Dava Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Veru.